Colorectal Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colorectal Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 10 (October)

1. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.
   J Clin Oncol, 25(28): 4379-86. [Abstract] [Full-text]
2. Retinoic acid inhibits beta-catenin through suppression of Cox-2: a role for truncated adenomatous polyposis coli.
   J Biol Chem, 282(40): 29394-400. [Abstract] [Full-text]
3. Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer.
   Int J Cancer, 121(10): 2192-7. [Abstract] [Full-text]
4. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis.
   Int J Cancer, 121(10): 2331-9. [Abstract] [Full-text]
5. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
   Int J Cancer, 121(10): 2301-6. [Abstract] [Full-text]
6. Differential involvement of destrin and cofilin-1 in the control of invasive properties of Isreco1 human colon cancer cells.
   Int J Cancer, 121(10): 2162-71. [Abstract] [Full-text]
7. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells.
   Int J Cancer, 121(10): 2172-80. [Abstract] [Full-text]
8. The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells.
   Int J Cancer, 121(10): 2140-52. [Abstract] [Full-text]
9. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
   J Natl Cancer Inst, 99(19): 1462-70. [Abstract] [Full-text]
10. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies.
    J Natl Cancer Inst, 99(19): 1471-83. [Abstract] [Full-text]
11. Primer: Applying the new postpolypectomy surveillance guidelines in clinical practice.
    Nat Clin Pract Gastroenterol Hepatol, 4(10): 571-8. [Abstract] [Full-text]
12. SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis.
    Cancer Res, 67(19): 9568-76. [Abstract] [Full-text]
13. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.
    Cancer Res, 67(19): 9443-54. [Abstract] [Full-text]
14. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
    Cancer Res, 67(19): 9380-8. [Abstract] [Full-text]
15. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA.
    Cancer Res, 67(19): 9364-70. [Abstract] [Full-text]
16. beta-catenin regulates multiple steps of RNA metabolism as revealed by the RNA aptamer in colon cancer cells.
    Cancer Res, 67(19): 9315-21. [Abstract] [Full-text]
17. Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation.
    Cancer Res, 67(19): 9286-93. [Abstract] [Full-text]
18. An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation.
    Cancer Res, 67(19): 9190-8. [Abstract] [Full-text]
19. Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer.
    Cancer Res, 67(19): 9107-16. [Abstract] [Full-text]
20. A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma.
    Cancer Res, 67(19): 9039-46. [Abstract] [Full-text]
21. Hypoxia upregulates carcinoembryonic antigen expression in cancer cells.
    Int J Cancer, 121(11): 2443-50. [Abstract] [Full-text]
22. Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence.
    Cancer Immunol Immunother, 56(12): 1993-2001. [Abstract] [Full-text]
23. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.
    Cancer Immunol Immunother, 56(12): 2003-16. [Abstract] [Full-text]
24. Third-line therapy for metastatic colorectal cancer.
    Cancer Chemother Pharmacol, 61(1): 1-13. [Abstract] [Full-text]
25. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
    Cancer Chemother Pharmacol, 61(1): 105-11. [Abstract] [Full-text]
26. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Cancer Chemother Pharmacol, 61(1): 75-81. [Abstract] [Full-text]
27. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients.
    Br J Cancer, 97(7): 971-7. [Abstract] [Full-text]
28. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.
    Br J Cancer, 97(7): 919-26. [Abstract] [Full-text]
29. CT colonography versus colonoscopy for the detection of advanced neoplasia.
    N Engl J Med, 357(14): 1403-12. [Abstract] [Full-text]
30. Multiple lymphomatous diverticulosis and comorbid chronic lymphocytic leukemia: novel manifestations of ileocolic mantle cell lymphoma.
    Int J Surg Pathol, 15(4): 408-13. [Abstract] [Full-text]
31. Primary malignant melanoma of the transverse colon: report of a case and review of the literature.
    Int J Surg Pathol, 15(4): 401-7. [Abstract] [Full-text]
32. p53 and mdm2 expression in colorectal carcinoma: a correlative analysis with clinical staging and histological parameters.
    Int J Surg Pathol, 15(4): 335-45. [Abstract] [Full-text]
33. Prevalence of colorectal cancer testing and screening in a multiethnic primary care population.
    J Community Health, 32(5): 311-23. [Abstract] [Full-text]
34. Colorectal cancer: imaging surveillance following resection of primary tumour.
    Cancer Imaging, 7: S143-9. [Abstract] [Full-text]
35. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
    Gastroenterology, 133(4): 1272-81. [Abstract] [Full-text]
36. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study.
    Gastroenterology, 133(4): 1099-105; quiz 1340-1. [Abstract] [Full-text]
37. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome.
    Gastroenterology, 133(4): 1093-8. [Abstract] [Full-text]
38. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors.
    Gastroenterology, 133(4): 1086-92. [Abstract] [Full-text]
39. Five-year colon surveillance after screening colonoscopy.
    Gastroenterology, 133(4): 1077-85. [Abstract] [Full-text]
40. Enhancement of anti-tumor activity in vitro and in vivo by CD150 and SAP.
    Mol Immunol, 45(3): 796-804. [Abstract] [Full-text]
41. Time spent walking and risk of colorectal cancer in Japan: the Miyagi Cohort study.
    Eur J Cancer Prev, 16(5): 403-8. [Abstract] [Full-text]
42. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer.
    Cancer, 110(8): 1697-707. [Abstract] [Full-text]
43. Mutations in the ataxia telangiectasia and rad3-related-checkpoint kinase 1 DNA damage response axis in colon cancers.
    Genes Chromosomes Cancer, 46(12): 1061-8. [Abstract] [Full-text]
44. The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers.
    Genes Chromosomes Cancer, 46(12): 1080-9. [Abstract] [Full-text]
45. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.
    J Clin Oncol, 25(29): 4593-602. [Abstract] [Full-text]
46. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
    J Clin Oncol, 25(29): 4581-6. [Abstract] [Full-text]
47. Actual 10-year survival after resection of colorectal liver metastases defines cure.
    J Clin Oncol, 25(29): 4575-80. [Abstract] [Full-text]
48. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
    J Clin Oncol, 25(29): 4557-61. [Abstract] [Full-text]
49. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    J Clin Oncol, 25(29): 4562-8. [Abstract] [Full-text]
50. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.
    J Clin Oncol, 25(29): 4569-74. [Abstract] [Full-text]
51. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Cancer Gene Ther, 14(11): 918-26. [Abstract] [Full-text]
52. Leiomyosarcoma of the anal canal: a case report.
    Int J Surg, 5(5): 345-50. [Abstract] [Full-text]
53. Transanal endoscopic microsurgery for rectal tumors: the St. Mary's experience.
    Am J Surg, 194(5): 694-8. [Abstract] [Full-text]
54. Outcomes of Veterans Affairs patients older than age 80 after surgical procedures for colon malignancies.
    Am J Surg, 194(5): 646-51. [Abstract] [Full-text]
55. Causes of high mortality in colorectal surgery: a review of episodes of care in Veterans Affairs hospitals.
    Am J Surg, 194(5): 639-45. [Abstract] [Full-text]
56. Physician-patient communication about colorectal cancer screening.
    J Gen Intern Med, 22(11): 1493-9. [Abstract] [Full-text]
57. Adenoma of anogenital mammary-like glands.
    J Am Acad Dermatol, 57(5): 896-8. [Abstract] [Full-text]
58. Colorectal intussusception secondary to sigmoid carcinoma in an adult.
    South Med J, 100(10): 1039-41. [Abstract] [Full-text]
59. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    J Clin Oncol, 25(30): 4793-9. [Abstract] [Full-text]
60. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    J Clin Oncol, 25(30): 4779-86. [Abstract] [Full-text]
61. Total mesorectal excision and management of rectal cancer.
    Expert Rev Anticancer Ther, 7(10): 1395-403. [Abstract] [Full-text]
62. Is finger palpation at operation indispensable for pulmonary metastasectomy in colorectal cancer?
    Ann Thorac Surg, 84(5): 1680-4. [Abstract] [Full-text]
63. Increased susceptibility of Sf1(+/-) mice to azoxymethane-induced colon tumorigenesis.
    Cancer Sci, 98(12): 1862-7. [Abstract] [Full-text]
64. Fish consumption, n-3 fatty acids, and colorectal cancer: a meta-analysis of prospective cohort studies.
    Am J Epidemiol, 166(10): 1116-25. [Abstract] [Full-text]
65. Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice.
    Int J Radiat Oncol Biol Phys, 69(4): 1231-7. [Abstract] [Full-text]
66. Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer.
    Int J Radiat Oncol Biol Phys, 69(4): 1167-72. [Abstract] [Full-text]
67. Leisure-time physical activity patterns and risk of colon cancer in women.
    Int J Cancer, 121(12): 2776-81. [Abstract] [Full-text]
68. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.
    Int J Cancer, 121(12): 2668-73. [Abstract] [Full-text]
69. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation.
    Int J Cancer, 121(12): 2808-14. [Abstract] [Full-text]
70. Hedgehog signaling pathway is inactive in colorectal cancer cell lines.
    Int J Cancer, 121(12): 2622-7. [Abstract] [Full-text]

© 2004-2008 Colorectal Cancer Research Today. All Rights Reserved.